Earnings call transcript: Nanobiotix’s FY 2025 turnaround driven by strategic moves

Nanobiotix reported FY2025 net loss of EUR 24.0m (improved from EUR 68.1m in 2024) and revenue of EUR 32.6m driven by a EUR 21.8m one-time accounting benefit from a Janssen licensing amendment. The company missed EPS expectations at -0.5069 vs forecast -0.3943, while R&D fell 43% to EUR 23.1m and cash was EUR 52.8m (projected runway into early 2028). Shares rose ~3.47% premarket to $31.94 (market cap ~$1.49bn) reflecting investor optimism on the strategic deal and royalty financing, but risks remain around EPS miss, liquidity (current ratio 0.63) and regulatory/clinical execution.

Analysis

Nanobiotix’s headline improvement appears to be a financing-and-structure story more than a sustainable operations turnaround; the market has already priced a high-probability regulatory/commercial outcome into the equity, creating asymmetric downside if J&J elects to slow or limit expansions. The royalty financing and licensing repricing materially shift where future cash flows land — more cash visibility for NBTX but a larger portion of upside effectively rerouted to non-equity claimants, compressing marginal equity returns on positive readouts.

From a competitive-dynamics standpoint, the real optionality is platform-level: success in localized radioenhancement de-risks a broad radiation-adjunct roadmap, but the partner (large pharma) controls scale, indication prioritization, and regulatory strategy — NBTX’s path to capture value therefore depends on third-party commercial decisions as much as on clinical efficacy. That handoff creates binary event risk concentrated in partner-managed trials and a time-to-monetize uncertainty that is longer and lumpier than headline liquidity improvements imply.

Key near-term market behavior to watch is positioning and vol: implied vol is likely elevated around the next program milestones, so equity moves will be magnified vs. fundamentals. For anyone sizing exposure, the correct framing is event-driven optionality with capped downside via structured options or hedges, not vanilla buy-and-hold — upside is concentrated around successful Phase readouts but downside is both valuation compression and revenue-share dilution if milestones disappoint.

Contrarian angle: consensus treats the accounting improvement as de-risking runway; we view it as de-levering operational burn but increasing dependency on partner execution and royalty amortization, which could leave equity returns hostage to timing and payout cadence. That makes small, protected, event-tied exposures superior to naked long positions today.

Key Decisions for Investors

• Event-driven long (NBTX): Buy a 9–12 month call spread on NBTX (buy ATM call / sell ~25–35% OTM call) sized to 1–2% of portfolio to capture upside if partner-managed trial data surprise positive; max loss = premium paid, expected upside >=3x if a clear positive readout triggers re-rating. Hedge tail risk by allocating 0.25% to an out-of-the-money protective put or a short-dated stop-loss at ~30% drawdown.
• Protective equity play (NBTX + puts): If you prefer stock exposure, buy NBTX shares but simultaneously purchase 12-month puts at ~40% OTM to cap catastrophic downside; thesis: limited equity dilution but capped upside due to royalty financing — this trade converts asymmetric equity risk into defined, limited loss for a modest cost.
• Dispersion / rotation (reduce biotech beta → SMCI/APP): Trim speculative biotech exposure (including NBTX) and redeploy proceeds into higher-quality growth names with cleaner earnings (e.g., long SMCI or APP options with 6–9 month expiries). Risk/reward: lower idiosyncratic binary risk, smaller but steadier upside tied to earnings beats rather than single clinical events.
• Event-driven short (selective, small): If you believe the market overprices execution odds and royalties materially cap equity payoff, consider a small-size short NBTX funded by selling covered-call premium (or using inverse-biotech exposure) sized <1% of portfolio — reward if readouts disappoint or milestones are delayed, but this is high-risk if data surprise positive so keep size tiny and set strict stop-loss levels.